Short reports

A patient with Graves' disease, thrombocytopenia and chronic hepatitis B

CC Szeto, CC Chow, GTC Ko, KY Li, VTF Yeung, CS Cockram

Summary

A 22-year-old Chinese man, a HBsAg carrier, presented with relapse of thyrotoxic Graves' disease complicated by thrombocytopenia and hepatitis. Platelet count and liver enzymes gradually improved following successful treatment of the thyrotoxicosis with radioactive iodine. Possible pathogenetic links and therapeutic implications are discussed.

Keywords: thyrotoxicosis, thrombocytopenia, chronic hepatitis

A 27-year-old Chinese man first presented in 1990 with thyrotoxic symptoms and goitre. He was a known HBsAg carrier with no risk factors and normal liver enzymes and biopsy. Hepatitis e antigen (HBeAg) was also positive. Thyroid-stimulating hormone was less than 0.02 mIU/l (normal 0.3–4.0), serum free triiodothyronine 22.3 pmol/l (normal 3.3–8.2). Serum free thyroxine was not checked. Thyroid antimicrosomal and antithyroglobulin antibodies were negative. Graves' disease was diagnosed and he was treated with propylthiouracil with good response. Propylthiouracil was continued for 18 months. His platelet count was $110 \times 10^9/l$ (normal 140–380) at that time.

The patient developed thyrotoxic symptoms again in early 1994. Serum thyroid-stimulating hormone concentration was 0.07 mIU/l, serum free thyroxine concentration was 34.7 pmol/l (normal 10.2–19.6). Propylthiouracil was restarted. Six weeks later he developed itchiness and nausea. Liver function tests showed an alanine transaminase of 874 IU/l (normal 0–58), alkaline phosphatase of 128 IU/l (normal 35–105), bilirubin $8 \mu\text{mol/l}$ (normal 0–15), and platelet count was $110 \times 10^9/l$. Serum free thyroxine concentration was 12.2 pmol/l. Propylthiouracil was stopped for possible drug-induced hepatitis. Alanine transaminase fell to 139 IU/l within a month. Radioactive iodine (8 mCi) was given in June, 1994. However, the serum free thyroxine concentration rose further to 167 pmol/l in August and he remained clinically thyrotoxic.

Lithium carbonate 400 mg bid was started as temporary antithyroid treatment. Serum free thyroxine concentration decreased to 50.9 pmol/l three weeks later, but rose again to 99.8 pmol after two months. He developed nausea and abdominal discomfort again. A rise

Figure 1 Sequential changes in serum free thyroxine concentration, platelet count and alanine transaminase concentrations. PTU=propylthiouracil

in alanine transaminase to 911 IU/l was noted, with normal alkaline phosphatase and bilirubin levels, while his platelet count fell to $62 \times 10^9/l$ (figure 1). Lithium was stopped. Alanine transaminase rose further to 1059 IU/l and platelet count fell to $10 \times 10^9/l$. Peripheral blood smear, clotting profile and abdominal ultrasound were unremarkable. He remained sero-positive for HBsAg and HBeAg. IgM anti-HAV, anti-HCV, anti-smooth-muscle, anti-mitochondrial, antinuclear and anticardiolipin antibodies were negative. Serum vitamin B12 and folate levels were normal. Bone marrow was reactive.

He developed recurrent epistaxis and gum bleeding. Repeated platelet transfusion was required. Five doses of intravenous gammaglobulin were given without effect. He received 15 mCi radioactive iodine in mid-September. Symptoms improved substantially and serum free thyroxine concentration fell to 25.5 pmol/l within four weeks. Platelet count rose to $72 \times 10^9/l$, and alanine transaminase fell to 399 IU/l. By November, the patient was totally asymptomatic. His platelet count was $112 \times 10^9/l$, alanine transaminase was 315 IU/l and serum free thyroxine concentration was

Department of
Medicine, Prince of
Wales Hospital, The
Chinese University of
Hong Kong, Shatin,
NT, Hong Kong
CC Szeto
CC Chow
GTC Ko
KY Li
VTF Yeung
CS Cockram

Accepted 7 February 1996

7.7 pmol/l. Replacement thyroxine was commenced. A summary of the biochemical changes are represented in figure 1.

Discussion

This case demonstrates possible interactions between thyrotoxicosis, thrombocytopenia, and chronic active hepatitis (figure 2). Either an immunological or a metabolic mechanism may account for the coexistence of these conditions.

While the first hepatitis episode was probably propylthiouracil-related, the second one was not. Hyperthyroidism *per se* has been reported to cause liver enzyme abnormalities,¹ mostly elevation of alkaline phosphatase. A hepatic picture in thyrotoxicosis is also possible, even without coexisting liver disease. Our patient was HBeAg positive, suggesting active viral replication. It has been suggested that patients with Graves' disease have genetically determined immunological fragility which may predispose to viral hepatitis.² We have not observed such a phenomenon, although both conditions are common in our locality. We are also unaware of previous reports of autoimmune thyroid diseases triggered by chronic hepatitis B.

The association between thyrotoxicosis and thrombocytopenia was first reported 60 years ago.³ About 40% patients with untreated thyrotoxicosis have a low platelet count.⁴ An autoimmune process was first suggested, although nonimmunologic mechanisms are now more generally accepted.^{5,6} Kurata and co-workers⁵ found that platelet survival was decreased in rats injected with triiodothyronine. They suggested that thyrotoxicosis could activate the reticuloendothelial system and hence cause platelet sequestration.

The cause of thrombocytopenia in our patient was not clear. Its response to radioactive iodine but not immunoglobulin suggest

Figure 2 Pathogenetic interaction of coexisting thyrotoxicosis, hepatitis and thrombocytopenia

Learning points

- thrombocytopenia associated with thyrotoxicosis may be due to coexisting immune destruction or, more commonly, shortened platelet survival due to nonimmune mechanisms
- in this case, the thrombocytopenia will usually subside after the thyrotoxicosis has been controlled. Splenectomy should not be considered until the patient is rendered euthyroid
- flare-up of hepatitis may be induced by thyrotoxicosis, and effective control of the latter condition may help the remission of hepatitis

nonimmunologic mechanisms. Folate deficiency and antiphospholipid antibody syndrome were excluded. Platelet-specific immunoglobulin was not measured. Its value in diagnosis is, however, doubtful.⁷ Active hepatitis may also cause splenic sequestration. The choice of therapy for thrombocytopenia in our patient was difficult. Intravenous immunoglobulin failed. Glucocorticoid was contraindicated because of active hepatitis. Since thyroid ablation has been reported to lead to recovery of the thrombocytopenia,⁸⁻¹⁰ we elected to give radioactive iodine therapy before pursuing other possibilities.

1 Fong TL, McHutchison JG, Reynolds TB. Hyperthyroidism and hepatic dysfunction: a case series analysis. *J Clin Gastroenterol* 1992; 14: 240-4.

2 Mancini A, De Marinis L, Fiumara C, et al. Ruolo dei meccanismi autoimmuni nella sindrome ipertiroidismoepatite virale: una possibile non casuale associazione. Revisione della letteratura e casistica personale. *Minerva Med* 1990; 81: 249-54.

3 Jackson AS. Acute hemorrhagic purpura associated with exophthalmic goiter. *JAMA* 1931; 96: 38-9.

4 Hymes K, Blum M, Lackner H, Karparkin S. Easy bruising, thrombocytopenia, and elevated platelet immunoglobulin G in Graves' disease and Hashimoto's thyroiditis. *Ann Intern Med* 1981; 94: 27-30.

5 Kurata Y, Nishioeda Y, Tsubakio T, Kitani T. Thrombocytopenia in Graves' disease: effect of T3 on platelet kinetics. *Acta Hematol* 1980; 63: 185-90.

6 Panzer S, Haubenstock A, Minar E. Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled platelet kinetics, and platelet-associated immunoglobulins G and M. *J Clin Endocrinol Metab* 1990; 70: 491-6.

7 Handin RL. Disorders of the platelet and vessel wall. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, ed. *Harrison's principles of internal medicine*, 13th edn. New York: McGraw-Hill Inc, 1994.

8 Adrouny A, Sandler RM, Carmel R. Variable presentation of thrombocytopenia in Graves' disease. *Arch Intern Med* 1982; 42: 1460-4.

9 Ma MX, Yu JR, Cai ZQ. Clinical analysis of 36 cases of coexistent hyperthyroidism with idiopathic thrombocytopenic purpura. *Chung Hua Nei Ko Tsa Chih* 1989; 28: 136-8.

10 Liechty RD. The thyrotoxicosis/thrombocytopenia connection. *Surgery* 1983; 94: 966-8.